N onalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions ranging from simple steatosis through nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. 1 Current evidence from a large single-center serial biopsy study, supported by a recent meta-analysis, indicates that approximately 40% of NAFLD cases will show progressive fibrosis during a median 6.6-year follow-up evaluation. 2, 3 Although the accumulation of various lipids in the liver is the prerequisite for NAFLD, recent evidence suggests that inflammatory biomarkers also could play a role in the development of NASH. 4 Currently, there are no approved pharmacologic therapies for managing NAFLD, although a number of promising agents are in trial. 5 Lifestyle interventions, incorporating weight loss and increased physical activity/exercise, remain the cornerstone of NAFLD management, [6] [7] [8] [9] however, implementation remains difficult. 10 Evidence supporting the effect of physical activity independent of weight loss is limited, impeding successful translation into clinical practice. Increasing physical activity through structured exercise has shown a significant beneficial effect on hepatic triglyceride content (HTGC). 7, 11, 12 To date, only 1 study has assessed the effect of exercise in biopsy-proven NASH and reported no change in HTGC or fibrosis. 9 However, the study did not include a control group and used the percentage of hepatocytes affected to assess HTGC, limiting sensitivity.
The primary objective of this randomized controlled trial was to determine the effects of exercise, without weight loss, on HTGC in adults with biopsy-confirmed NASH. The secondary aims were to determine the effect of exercise on mediators of NASH: abdominal adiposity, glucose control, circulating markers of inflammation, and noninvasive markers of fibrosis.
Materials and Methods
Thirty-one patients with histologically characterized NASH (age, 59 AE 12 y; body mass index [BMI], 35 AE 5 kg/m 2 ) were screened for study entry. Patients with evidence of other liver disease or a history of excessive alcohol consumption (alcohol intake >20 g/d for women or >30 g/d for men) were excluded ( Table 1 ). The study protocol was approved by the Sunderland Research Ethics Committee, UK, and all patients provided written informed consent. Liver biopsy specimens were scored histologically by 2 expert histopathologists (A.D.B. and D.T.) according to the NASH Clinical Research Network criteria. 13 The NAFLD activity score was graded between 0 and 8, and fibrosis was staged from 0 to 4 as previously performed 14 ( Table 2 ). Other exclusion criteria included the following: heart or kidney disease, implanted ferrous metal, pre-existing medical conditions preventing participation in the exercise program, insulin-sensitizing treatment, or dietary change over the preceding 6 months. Five patients were excluded during screening because of abnormal electrocardiographs and 1 patient withdrew because of claustrophobia during magnetic resonance imaging scanning (see Consolidated Standards of Reporting Trials diagram, Supplementary Figure 1) .
Twenty-six sedentary (<60 min/wk of moderatevigorous activity) patients were assigned randomly using a permuted blocks method to either exercise (n ¼ 13) or standard care (n ¼ 13) (Supplementary Figure 1) . Participant characteristics are summarized in Table 1 . 
Study Intervention
Exercise was supervised by an accredited exercise specialist and recorded to ensure adherence 3 times per week on nonconsecutive days for 12 weeks. 18, 19 The exercise program consisted of aerobic (cycling) and resistance training, and is detailed in Supplementary Methods. All patients were instructed not to alter their diet and to maintain their current weight throughout the study.
Statistics
Sample size was calculated based on change in HTGC from previous data in NAFLD 12 ; an 80% power of detecting a 10% relative difference between group change in liver HTGC with a SD of 9.0 and a 1-sided 0.05 significance required n ¼ 11 per group. We recruited 13 per sample to allow 2 drop-outs per group. Normality was assessed using a Kolmogorov-Smirnov test and logarithmically transformed if not normally distributed. Between-group differences were evaluated using an unpaired t test and within-group differences using a paired t test (2 way). Treatment Â time interactions were assessed using a 2-way analysis of variance. Analyses of covariance were used to test for between-group differences in outcome variables while controlling for baseline values. Bivariate correlations using Pearson rank correlations were conducted to investigate any associations between HTGC, body composition, triglyceride levels, glucose control, biomarkers of inflammation, and NAFLD fibrosis marking systems. Statistical significance was set at a P value of less than .05. Statistical analyses were performed using SPSS statistical analysis software (version 19; IBM, Chicago, Illinois). All authors had access to the study data and reviewed and approved the final manuscript.
Results
Twenty-six patients were randomized, with 2 patients withdrawing owing to pre-existing knee and back problems (Supplementary Figure 1) . Twenty-four patients completed the study, with all subjects in the exercise group completing the 36-session exercise program. The control and exercise groups were well matched (Table 1) , with no significant differences in age (51 AE 16 vs 54 AE 12 y) or BMI (33 AE 5 vs 33 AE 7 kg/m 2 ). Baseline histologic scores and fibrosis staging are shown in Table 2 .
Body Mass Index, Body Composition, and Hepatic Triglyceride Content
During the study, BMI, weight, and subcutaneous fat remained constant in both groups (Tables 1 and 3 ). Visceral fat decreased by 12% in the exercise group and increased by 7% in the control group (P < .01) ( Figure 1 and Table 3 ). Exercise increased lean body mass by 4% vs 0% in the control group (P < .05), and reduced fat mass by 6% vs 0% in the control group, although the latter was not statistically significant. Exercise produced a 16% reduction in HTGC compared with an 8% increase in the control group (P < .05) ( Figure 1 and Table 3 ).
Blood Lipid and Liver Enzyme Levels
There was a time by treatment interaction for triglyceride levels, with exercise eliciting a reduction of 23% vs a 13% increase in the control group (P < .05). There was also a significant reduction of 13% in g-glutamyltransferase after exercise (P < .05). No other significant changes in blood biochemistry were observed in either group (Table 1) .
Metabolic Control
The exercise group showed a -17% vs -7% reduction in fasting insulin level, and decreased homeostatic model assessment of insulin resistance of -17% vs þ6%, although these values did not reach statistical significance (Table 3 ). There were no differences in any other glucose control variables after the intervention in either group or between groups (Table 3) . No time by treatment interaction for fasting blood glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment of insulin resistance, or glucose area under the curve for the frequently sampled oral glucose tolerance test were observed (Table 3) .
Circulatory Inflammation and Noninvasive Fibrosis Markers
There was no significant time by treatment interaction for exercise on circulating inflammatory biomarkers, CK-18, hsCRP, or the noninvasive markers of fibrosis (NAFLD fibrosis score, aspartate aminotransferase [AST]/alanine aminotransferase [ALT] ratio, and enhanced liver fibrosis test) ( Table 4) .
Correlations
HTGC was associated positively with visceral fat at baseline and after the intervention (r ¼ 0.49, P ¼ .01; and r ¼ 0.36, P ¼ .04, respectively). There was also a positive correlation between the changes in HTGC and visceral fat after the intervention (r ¼ 0.39, P ¼ .03). There were no other significant correlations between HTGC, body composition, glucose control, biomarkers of inflammation, or fibrosis markers at baseline or postintervention.
Discussion
This RCT examined the effects of exercise, independent of weight loss, in adults with histologically confirmed NASH. The data show that 12 weeks of exercise resulted in the following: (1) a 16% reduction in liver fat, (2) a 12% reduction in visceral fat, (3) a 23% reduction in circulating triglyceride levels, and (4) a 4% increase in lean body mass. However, 12 weeks of exercise had no significant effect on glucose control, circulating markers of inflammation, liver enzyme levels, or NAFLD activity score.
Lifestyle modification combining dietary change and exercise produces a robust reduction in HTGC and even reversal of inflammation with more than 10% weight loss in people with NASH, 6,8 data on exercise without weight loss are lacking. We show that 12 weeks of exercise therapy resulted in a 16% reduction in HTGC, independent of weight loss in people with NASH. The changes in HTGC reported here are in line with previous reports of exercise without weight loss in people with NAFLD 11, 12 and show the effectiveness of exercise in reducing HTGC in NASH. Although consistent with earlier reports in NAFLD, our observation contrasts with the only other study looking specifically at exercise in NASH, which reported an apparent stability of HTGC after 6 months of exercise. 9 The difference between these studies most likely can be explained by the greater sensitivity of proton magnetic resonance spectroscopy (as used in this study) vs histologic assessment of the percentage of hepatocytes affected in the small number of cases in the previous study and the well-controlled design of the present study. Our HTGC data suggest that exercise may hold therapeutic benefits for people with NASH.
Although the reduction in HTGC with exercise is encouraging, the changes reported here should be placed in context of studies using a combination of weight loss and exercise in NAFLD, which see a relative reduction of between 42% and 81% in HTGC after a mean weight reduction of 4% to 14%. 7 Weight loss and exercise yielding a 10% reduction in body weight can reverse NASH, 6, 8 highlighting the summative benefits of weight loss and exercise. Although weight loss undoubtedly is effective in reducing HTGC, the difficulty of maintaining weight loss in the long term is well documented. 10 As such, the optimal clinical value of exercise upon liver health for people with NASH appears likely to be an adjunct to caloric restriction. However, exercise without weight loss may represent an alternative therapy for patients who find weight loss difficult.
The mechanisms underlying the change in HTGC after exercise in NASH reflect changes in energy balance, circulatory lipids, and insulin sensitivity. Without any change in body weight, exercise reduced visceral fat by 12%. To date, only 1 study has assessed the effects of exercise in biopsy-proven NASH, 9 however, the current RCT assessed the effects of exercise on HTGC, metabolic control, body composition, alongside inflammatory and fibrosis markers in patients with NASH. Visceral fat is reported to be linked directly with liver inflammation and fibrosis, independent of insulin resistance and hepatic steatosis. 20 The precise mechanism of how visceral fat applies its detrimental effects on liver metabolism and fibrotic and inflammatory consequences remains unclear, although an influx of fatty acids and synthesis of cytokines and adipokines has been shown to promote liver lipid accumulation, insulin resistance, and inflammation. 20, 21 The present data support the close relationship between visceral fat and HTGC, with baseline visceral fat correlating with HTGC and the change in visceral fat with exercise correlating with the change in HTGC.
The apparent stability in metabolic control here is surprising given the reduction in HTGC and visceral fat, and the close link between HTGC, hepatic insulin sensitivity, and endogenous glucose production. 22, 23 Despite a 16% reduction in HTGC, 19 patients remained above the clinical 5% HTGC diagnosis, suggesting that a larger reduction in HTGC is required to improve hepatic insulin sensitivity and glucose control significantly, as recently shown. 24, 25 Irrespective of the effects of exercise on glycemic control, the selective reduction of both visceral fat and HTGC with exercise, independent of weight loss, supports exercise as an adjunct therapy for NASH, as previously shown in NAFLD. 11, 12 In this study there was a reduction in CK-18, a marker of apoptosis and a defining pathologic feature of NASH, known to correlate with liver damage and fibrosis. 15 However, TNF-a, IL6, and hsCRP all remained stable in the exercise group, despite changes in HTGC and visceral fat. Although increased liver lipid is a prerequisite of NASH, 26 dysregulated cytokine metabolism plays an important role in disease progression. 4 Exercise studies in coronary artery disease, type 2 diabetes mellitus, and NAFLD have reported reductions in circulating cytokine levels (IL6 and TNF-a) 27, 28 and CK-18, 29 raising the possibility of a protective effect of exercise. However, a combined weight loss and exercise program in people with NASH also showed a stability in circulatory cytokine levels, with the exception of IL6, which was reduced. 30 Importantly, circulatory inflammatory markers do not represent inflammation inside of the liver. Because hepatic inflammatory markers were not assessed directly, HTGC may represent a better biomarker of free fatty acid flux, oxidative stress, and ER stress that result in steatosis and progressive liver damage. 31 Although there are clear biological links between inflammation and NASH, further studies are required to understand how lifestyle management may be optimized to address these.
Liver enzyme levels (ALT, AST) and noninvasive scores of liver disease (ALT/AST ratio, NAFLD fibrosis score, and an increased liver fibrosis test) did not change with 12 weeks of exercise therapy. Furthermore, changes in HTGC were not correlated with liver enzyme levels or noninvasive scores of liver disease. Our study used liver enzyme levels and noninvasive measures of liver disease because follow-up biopsies to assess liver histology were not ethically permitted. However, biopsy data show that significant weight loss as a result of calorie restriction and exercise improves liver histology. 6, 8 The lack of change in liver enzyme levels and biomarkers of liver disease after exercise suggest that exercise without weight loss may be insufficient to influence liver fibrosis directly. However, without a follow-up biopsy it is difficult to truly ascertain the impact of exercise alone on NASH. The present data support longer and larger studies investigating the differential and combined effects of exercise and weight loss in NASH to confirm their effects on disease progression.
Limitations
The present study was not without limitation. Liver fibrosis was not measured directly from biopsy after exercise. However, because recent work has suggested that steatosis and NASH may be more interchangeable than previously thought 2 it was ethically difficult to justify exposing volunteers to the risk of a repeat biopsy within such a short period of time. Although powered sufficiently for the primary outcome, the sample size may be insufficient to define secondary outcomes. The length of the study, although comparable with previous exercise studies in NAFLD, may not have been long enough in duration to observe any improvements in histology and circulating inflammation in NASH.
Conclusions
Exercise was well tolerated and reduced HTGC, visceral fat, and circulating triglycerides in adults with biopsy-proven NASH, independent of weight loss, but without any apparent impact on circulating markers of inflammation or noninvasive scores of liver disease. These data suggest that increased exercise in the absence of weight loss is effective at reducing HTGC, but may be less efficacious at ameliorating steatohepatitis over a 12-week program. Clinically, exercise has a significant beneficial effect on HTGC and visceral fat. However, the optimal clinical value of exercise for people with NASH appears likely to be an adjunct to caloric restriction.
Supplementary Material
Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at www.cghjournal.org, and at http://dx.doi.org/10.1016/j.cgh.2016.07.031.
